Can we afford to lose the pharmaceutical industry in the EU?
- 1 August 1996
- journal article
- Published by Emerald Publishing in European Business Review
- Vol. 96 (4) , 18-25
- https://doi.org/10.1108/09555349610124628
Abstract
Suggests that the population of the EU will still need drugs whether or not the EU continues to have a pharmaceutical industry. Various policies trying to control health service drugs bills have affected the drugs industry: increasingly the effects are adverse. The EU Commission is now taking an increasing interest in health care and pharmaceutical industry policy. It is therefore of some urgency to open the debate up by beginning to signal what the EU stands to lose if it loses the pharmaceutical industry in the EU. Although it is highly improbable that the EU will lose all the present pharmaceutical industry in the EU it is likely that it will lose some of it in the next five years, and it is almost certain that the industry in the EU will continue to yield with respect to industry in North America, the Pacific Basin and Asia.Keywords
This publication has 10 references indexed in Scilit:
- The Regulatory ChallengeSouthern Economic Journal, 1996
- Recent developments in regulating the pharmaceutical business in the EUEuropean Business Review, 1996
- International R&D spilloversEuropean Economic Review, 1995
- North-South R&D SpilloversPublished by National Bureau of Economic Research ,1995
- The Regulatory ChallengePublished by Oxford University Press (OUP) ,1995
- Learning-by-Doing Spillovers in the Semiconductor IndustryJournal of Political Economy, 1994
- The Pharmaceutical Industry and Health Reform: Lessons From EuropeHealth Affairs, 1994
- Pricing, Profits, and Technological Progress in the Pharmaceutical IndustryJournal of Economic Perspectives, 1993
- World Development Report 1993Published by World Bank ,1993
- Europe After 1992: Implications For PharmaceuticalsHealth Affairs, 1991